Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics

NCT02414750 is registered in ClinicalTrials.gov with Netherlands Working Group on Immunotherapy of Oncology as lead sponsor.

NCT NCT02414750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02414750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics
Lead sponsor
Netherlands Working Group on Immunotherapy of Oncology
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2014
Completion date
November 30, 2020
Enrollment
78 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma